The approval of a new medical marijuana extract in Portugal is a positive development for Tilray, potentially expanding its market and product offerings in Europe. Despite this, the stock was trading lower in the pre-market session, which could be due to broader market conditions or investor sentiment. The long-term impact is likely positive as the company strengthens its European presence.